CN101973938B - C环氢化青藤碱衍生物及其制备方法和应用 - Google Patents
C环氢化青藤碱衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN101973938B CN101973938B CN201010268980A CN201010268980A CN101973938B CN 101973938 B CN101973938 B CN 101973938B CN 201010268980 A CN201010268980 A CN 201010268980A CN 201010268980 A CN201010268980 A CN 201010268980A CN 101973938 B CN101973938 B CN 101973938B
- Authority
- CN
- China
- Prior art keywords
- hydrogenated
- tuduranine
- sinomenine
- sinomenine derivate
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical class C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000007341 Heck reaction Methods 0.000 claims abstract description 6
- KUECBJOPWMRHEX-CQSZACIVSA-N Tuduranine Chemical compound C1C2=CC=C(O)C=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1NCC3 KUECBJOPWMRHEX-CQSZACIVSA-N 0.000 claims description 77
- KUECBJOPWMRHEX-UHFFFAOYSA-N Tuduranine Natural products C1C2=CC=C(O)C=C2C2=C(OC)C(OC)=CC3=C2C1NCC3 KUECBJOPWMRHEX-UHFFFAOYSA-N 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 18
- -1 aromatic aldehyde oxime Chemical class 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910000497 Amalgam Inorganic materials 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 238000006352 cycloaddition reaction Methods 0.000 claims description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003934 aromatic aldehydes Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 abstract description 17
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 abstract description 15
- 229930002966 sinomenine Natural products 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 201000003068 rheumatic fever Diseases 0.000 abstract description 6
- 125000001424 substituent group Chemical group 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 206010003246 arthritis Diseases 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000007259 addition reaction Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000010453 quartz Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 0 Cc1c(*)c(*)c(*)c(C2=NOC[C@@]2C(OC)=O)c1* Chemical compound Cc1c(*)c(*)c(*)c(C2=NOC[C@@]2C(OC)=O)c1* 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010039361 Sacroiliitis Diseases 0.000 description 2
- 241001643409 Sinomenium acutum Species 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- MFKPWBJXKCSPGK-KNORBDTNSA-N sinococuline Chemical compound C([C@@H]1NCC2)C3=CC=C(OC)C(O)=C3[C@@]32C1=C(OC)[C@@H](O)[C@@H](O)C3 MFKPWBJXKCSPGK-KNORBDTNSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- KCJJFVNEBNMVHJ-YPTPCZDSSA-N (1S,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-13-ol Chemical class C1C(O)CC[C@H]2[C@]3([H])NCC[C@@]21C1=CC=CC=C1C3 KCJJFVNEBNMVHJ-YPTPCZDSSA-N 0.000 description 1
- XUSCOHKHRDQKCI-ARFHVFGLSA-N (1S,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-13-one Chemical class C1C(=O)CC[C@H]2[C@]3([H])NCC[C@@]21C1=CC=CC=C1C3 XUSCOHKHRDQKCI-ARFHVFGLSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- BQJCRHHNABKAKU-QHQPWPDESA-N (4s,4as,7r,7as,12br)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound O([C@@H]1[C@@H](C=C[C@@H]23)O)C4=C5[C@]12CCN(C)[C@H]3CC5=CC=C4O BQJCRHHNABKAKU-QHQPWPDESA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- REKJPVUFKQYMHW-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC(C(F)(F)F)=C(C(O)=O)S1 REKJPVUFKQYMHW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000002131 composite material Chemical group 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 150000002611 lead compounds Chemical group 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000003810 morphinanes Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Abstract
本发明公开了一种C环氢化青藤碱A环1位引入卤素、碳碳双键取代基、异噁唑啉杂环取代基的衍生物及其合成方法和应用。本发明的C环氢化青藤碱衍生物是以青藤碱为母体,通过合成技术(包括微流控合成),在青藤碱1位通过Heck反应和1,3-偶极环加成反应生成青藤碱衍生物。所得化合物具有较好的抗炎活性,具有用于关节炎,风湿性关节炎及其抗炎药物的潜力。
Description
技术领域
本发明涉及青藤碱衍生物及其制备方法和应用,具体涉及C环氢化青藤碱衍生物及其制备方法和应用。
背景技术
青藤碱[(9α,13α,14α)-7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-mophinan-6-one,Sinomenine]是从防己科植物青藤及毛青藤的干燥藤茎中提取的一种异喹啉类生物碱,青藤碱及其衍生物具有镇痛镇静、镇咳局麻、降血压、抗炎作用,为植物中很强的组织胺释放剂,在临床上被应用于治疗风湿性和类风湿性关节炎;动物实验提示在休克和器官损害中有保护作用。其结构式如下:
通过对青藤碱的结构修饰,合成结构新颖、筛选活性更高的衍生物是药物化学目前研究的热点之一。如陈磊等“微生物转化合成羟基化青藤碱及其条件优化”(北京中医药大学学报2008/10);康姚洁等“青藤碱对高糖处理下的血管内皮细胞功能的影响”(第四军医大学学报2009/21);王毅等“青藤碱对人外周血CD4+T淋巴细胞增殖和细胞内Ca2+浓度影响的体外研究”(中华细胞与干细胞移植2009/01);吴敏等“青藤碱与卡铂对宫颈癌Hela细胞增殖的协同抑制研究”(实用妇产科杂志2009/08);褚建波等“青藤碱凝胶剂透皮吸收的研究”(中国现代应用药学2009/08);邓艳平等“盐酸青藤碱缓释组合微丸系统的研究”(中国药科大学学报2009/03)。从目前的研究成果来看,对C环结构改造的比较多,如国内的李玉峰等“从青藤碱制备具有(+)-C-Normorphinan骨架的化合物”(有机化学2009/02),对C环进行了缩环研究;国外的Cantrell,G.L.等“Process for thepreparation of 6-hydroxymorphinan compounds from 6-ketomorphinans”(U.S.Pat.Appl.Publ.,2009312552,17 Dec 2009),在青藤碱C环的6位生成了一个羟基;Whittall,J.等“Production of(+)-morphine from(-)-sinomenine”(Brit.UK Pat.Appl.,2392670,10Mar 2004),把青藤碱C环的碳碳双键还原成了碳碳单键;Hitotsuyanagi,Y.等“Syntheses of Antitumor Morphinane Alkaloids,Sinococuline and6-epi-,7-epi-,and 6-epi-7-epi-Sinococuline,from Sinomenine”(Journal of OrganicChemistry,60(14),4549-58;1995),也报道了青藤碱C环和A环4位羟基的结构修饰。对A环的结构修饰,目前主要都集中在4位羟基上,杨健等“青藤碱衍生物的合成及其镇痛抗炎作用定量构效关系”(武汉大学学报2009/01),以青藤碱为先导化合物,在其A环4位酚羟基进行酰化、醚化合成了七种青藤碱衍生物。对青藤碱D环的结构修饰也有报道,比如17为N原子的烃基化、磺酰化(CN.1785976A;CN.1785977A;CN.1962638A)。对A环1位的结构修饰研究的不多,除了罗娟等(CN.1948291A;有机化学2007/05),对1为进行了大量的胺甲基化修饰外,没见其他系统的研究报道。因此对青藤碱A环1位的结构修饰还有很大的空间,而利用目前热门的微流控合成技术对青藤碱的结构修饰至今更未见报道。
发明内容
发明目的:针对现有技术中存在的不足,本发明的第一个目的是提供一种青藤碱A环衍生物,第二个目的是提供这种青藤碱A环衍生物的制备方法,第三个目的是提供这种青藤碱A环衍生物的应用。
技术方案:为了实现上述发明目的,本发明采用的技术方案如下:
一种C环氢化青藤碱衍生物,结构如下:
本发明的C环氢化青藤碱衍生物具有如下结构:
制备A环1位引入卤素取代基的青藤碱C环氢化青藤碱衍生物方法为青藤碱锌汞齐还原成C环氢化青藤碱,与NIS反应,生成1碘代C环氢化青藤碱。
制备A环1位引入碳碳双键取代基的C环氢化青藤碱衍生物方法为:首先以青藤碱为母核,锌汞齐还原成C环氢化青藤碱,与N-碘代丁二酰亚胺反应,得到1位碘取代的C环氢化青藤碱;再在微反应器中,在醋酸钯催化下与丙烯酸酯进行Heck反应,生成1位碳碳双键取代的C环氢化青藤碱衍生物。
制备A环1位引入异噁唑啉杂环取代基的C环氢化青藤碱衍生物的方法为:
1)首先以青藤碱为母核,锌汞齐还原成C环氢化青藤碱,与N-碘代丁二酰亚胺反应,得到1位碘取代的C环氢化青藤碱,再在微反应器中,在醋酸钯催化下与丙烯酸甲酯进行Heck反应,生成1位碳碳双键取代的C环氢化青藤碱衍生物。
2)在微反应器1中生成1位碳碳双键取代的C环氢化C环氢化青藤碱衍生物的同时,在微反应器2中进行芳醛肟和N-氯代丁二酰亚胺的反应,生成氯肟。
3)微反应器1中生成的碳碳双键取代的C环氢化青藤碱衍生物与微反应器2中生成的氯肟,在微反应器3中,进行1,3-偶极环加成反应,生成1位为异噁唑啉杂环取代基的C环氢化青藤碱衍生物。芳醛肟由相应的芳醛和盐酸羟氨反应制得,其特征结构式如下:
其中R3~R7为相同或不同的下列取代基:H、甲基的C1~4的烷基、甲氧基的C1-4的烷氧基、氯、溴、碘等。
一种上述的制备方法的专用装置,包括微量注射泵、注射器、T-型混合器、接头、石英毛细管和加热装置;所述的注射器设置在微量注射泵上,T-型混合器通过接头与注射器相通的石英毛细管相连接,所述的加热装置为油浴加热器。
上述的C环氢化青藤碱衍生物在用于制备治疗关节炎,风湿性关节炎及其抗炎药物中的应用。
有益效果:本发明的C环氢化青藤碱衍生物是以青藤碱为母体,通过合成技术(包括微流控合成),在青藤碱1位通过Heck反应和1,3-偶极环加成反应生成青藤碱衍生物。所得化合物具有较好的抗炎活性,具有用于关节炎,风湿性关节炎及其抗炎药物的潜力。
附图说明
图1是用于合成C环氢化青藤碱A环1位引入碳碳双键取代基的青藤碱衍生物的微反应器装置图。
图2是用于合成C环氢化青藤碱A环1位引入异噁唑啉杂环取代基的青藤碱衍生物的微反应器装置图。
具体实施方式
下面结合具体实施例来对本发明做进一步的解释。
实施例1:1-碘代C环氢化青藤碱的合成
将3mL浓盐酸稀释至60mL,加入4g HgCl2,溶解后,倒入盛有60g Zn的500mL圆底烧瓶中,摇荡5min后,倾去水,用浓盐酸洗涤一次,得锌汞齐。称取青藤碱盐酸盐16g,溶解在120mL盐酸溶液中(40mL水+80mL浓盐酸),倒入锌汞齐中,搅拌下回流5h,补加40mL浓盐酸后,继续回流5h。反应完成后,冷却,用NH3·H2O调节pH=9-10,用二氯甲烷萃取,合并二氯甲烷,用无水硫酸钠干燥,旋转蒸发,得到粗产品,用DCM∶EA∶CH3OH∶NH3·H2O=30∶30∶2∶1的展开剂柱层析分离得到C环氢化青藤碱。室温下,将5.74g C环氢化青藤碱溶于160mL的二氯甲烷中,搅拌下,于5min中内慢慢加入4.7g的NIS,继续搅拌5min,加入120mL的Na2S2O3饱和溶液,搅拌5min,分出二氯甲烷层,分别用适量水、饱和食盐水洗涤,用无水Na2SO4干燥,旋转蒸发,得到黄色固体,产物进一步柱层析纯化,得到1-碘代C环氢化青藤碱4,产率为84%。
mp:142-144℃;ESI-MS m/z:414[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.24(1H,s),3.86(3H,s),3.39(1H,d,J=12.2Hz),3.29(1H,br),2.94(1H,dd,J1=12.2Hz,J2=2.9Hz),2.79(2H,m),2.63(3H,s),2.36-2.28(1H,m),2.21-2.16(1H,m),2.05-1.96(1H,m),1.90-1.85(1H,m),1.63-1.37(4H,m),1.25-1.05(3H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:146.1,144.9,129.1,125.2,119.6,87.9,60.5,56.4,48.1,42.9,41.5,37.3,35.2,34.9,32.5,26.0,25.5,22.3ppm
实施例2:C环氢化青藤碱A环1位引入碳碳双键取代基的青藤碱衍生物6a-6i的合成
如图1所示:将反应物用混合溶剂DMF/Et3N(5∶1 v/v)配制成2mL、0.5M的反应液:1-碘代C环氢化青藤碱4(413mg,1mmol);Pd(OAc)2(11.2mg,0.05mmol);PPh3(26.2mg,0.1mmol);丙烯酸酯(1mmol)。将盛有反应液的注射器置于微量注射泵上,设置流速为8μL/min;石英毛细管微反应器置于油浴中,油浴温度85℃;反应液流出时,用水立即淬灭。待反应完成后,旋掉溶剂和水,加入10mL乙酸乙酯,用饱和食盐水洗涤(3×5mL),无水硫酸钠干燥,浓缩,用硅胶柱分离,展开剂为:二氯甲烷/甲醇,得到C环氢化青藤碱1位肉桂酸酯衍生物6a-6i。
衍生物6a:产率:93%;mp:230-232℃;ESI-MS m/z:370[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:8.04(1H,d,J=15.6Hz),6.96(1H,s),6.23(1H,d,J=15.6Hz),3.89(3H,s),3.80(3H,s),3.36(1H,m),3.01-2.91(2H,m),2.75-2.67(1H,m),2.55-2.49(1H,m),2.39(3H,s),2.10-2.01(1H,m),1.83-1.09(10H,m)ppm;13CNMR(75MHz;CDCl3;TMS)δ:167.7,146.8,144.9,142.3,132.1,126.0,123.1,116.1,106.0,57.6,55.9,51.6,47.5,45.6,42.5,37.7,37.4,36.5,26.9,26.3,22.9,22.0ppm.
衍生物6b:产率:91%;mp:173-175℃;ESI-MS m/z:384[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:8.02(1H,d,J=15.6Hz),6.96(1H,s),6.23(1H,d,J=15.6Hz),4.25(2H,q,J=7.1Hz),3.87(3H,s),3.36(1H,m),3.00-2.92(2H,m),2.75-2.67(1H,m),2.55-2.50(1H,m),2.39(3H,s),2.10-2.01(1H,m),1.84-1.07(10H,m),1.32(3H,t,J=7.1Hz)ppm;13C NMR(75MHz;CDCl3;TMS)δ:167.3,146.9,145.0,142.0,131.9,125.9,123.1,116.5,106.0,60.3,57.7,55.9,47.5,45.5,42.5,37.7,37.3,36.5,26.8,26.3,22.9,22.0,14.3ppm.
衍生物6c:产率:92%;mp:142-144℃;ESI-MS m/z:412[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:8.02(1H,d,J=15.6Hz),6.96(1H,s),6.23(1H,d,J=15.6Hz),4.19(2H,t,J=6.6Hz),3.88(3H,s),3.38(1H,m),3.00-2.90(2H,m),2.74-2.66(1H,m),2.54-2.49(1H,m),2.38(3H,s),2.10-2.00(1H,m),1.82-1.07(14H,m),0.95(3H,t,J=7.3Hz)ppm;13C NMR(75MHz;CDCl3;TMS)δ:167.4,146.9,145.0,142.0,131.9,125.9,123.1,116.5,106.0,64.3,57.6,55.9,47.5,45.5,42.4,37.7,37.3,36.5,30.7,26.7,26.3,22.9,22.0,19.1,13.7ppm.
衍生物6d:产率:89%;mp:169-171℃;ESI-MS m/z:412[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:8.03(1H,d,J=15.6Hz),6.96(1H,s),6.22(1H,d,J=15.6Hz),3.97(2H,d,J=6.6Hz),3.88(3H,s),3.36(1H,m),2.99-2.87(2H,m),2.72-2.64(1H,m),2.54-2.41(2H,m),2.36(3H,s),2.07-0.89(11H,m),0.96(6H,d,J=6.6Hz)ppm;13C NMR(75MHz;CDCl3;TMS)δ:167.4,146.9,145.0,142.1,132.2,126.1,123.1,116.3,106.0,70.5,57.6,55.9,47.5,46.6,45.7,42.5,37.8,37.4,36.6,27.8,26.9,26.4,22.9,22.0,19.1ppm.
衍生物6e:产率:84%;mp:176-178℃;ESI-MS m/z:412[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:7.95(1H,d,J=15.6Hz),6.94(1H,s),6.15(1H,d,J=15.6Hz),3.86(3H,s),3.35(1H,m),2.96(1H,d,J=18.4Hz),2.85(1H,m),2.68-2.60(1H,m),2.48-2.43(1H,m),2.34(3H,s),2.05-0.90(11H,m),1.51(9H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:166.8,146.7,144.9,141.2,132.1,126.0,123.1,118.1,105.9,80.2,57.5,55.9,47.5,45.8,42.6,37.8,37.5,36.6,28.2,26.9,26.4,22.9,21.9ppm.
衍生物6f:产率:87%;mp:151-153℃;ESI-MS m/z:414[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:8.05(1H,d,J=15.6Hz),6.95(1H,s),6.28(1H,d,J=15.6Hz),4.34(2H,t,J=4.5Hz),3.85(3H,s),3.65(2H,t,J=4.5Hz),3.40(3H,s),3.34(1H,m),2.96(1H,d,J=18.4Hz),2.87(1H,m),2.71-2.63(1H,m),2.50-2.45(1H,m),2.35(3H,s),2.06-1.06(11H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:167.3,147.1,145.0,142.6,132.3,126.1,122.9,115.8,106.0,70.5,63.3,58.9,57.6,55.9,47.5,45.7,42.5,37.8,37.4,36.6,26.9,26.4,22.9,22.0ppm.
衍生物6g:产率:90%;mp:148-150℃;ESI-MS m/z:440[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:8.03(1H,d,J=15.6Hz),6.96(1H,s),6.21(1H,d,J=15.6Hz),4.19(2H,t,J=6.6Hz),3.89(3H,s),3.36(1H,m),3.00-2.89(2H,m),2.73-2.65(1H,m),2.54-2.47(1H,m),2.38(3H,s),2.10-0.85(22H,m)ppm;13CNMR(75MHz;CDCl3;TMS)δ:167.4,146.8,144.9,142.1,132.2,126.0,123.1,116.5,106.0,64.5,57.6,55.9,47.5,45.8,42.6,37.8,37.5,36.6,31.4,28.6,26.9,26.4,25.6,22.9,22.5,22.0,13.9,11.7ppm.
衍生物6h:产率:86%;mp:159-161℃;ESI-MS m/z:440[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:7.99(1H,d,J=15.6Hz),6.95(1H,s),6.19(1H,d,J=15.6Hz),4.85(1H,m),3.86(3H,s),3.35(1H,m),2.98-2.89(2H,m),2.73-2.65(1H,m),2.52-2.47(1H,m),2.37(3H,s),2.06-0.96(21H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:166.8,146.8,145.0,141.8,132.0,126.0,123.1,117.0,106.0,72.6,57.6,55.9,47.5,45.7,42.5,37.7,37.4,36.6,31.7,26.9,26.4,25.3,23.7,22.9,22.0ppm.
衍生物6i:产率:87%;mp:125-127℃;ESI-MS m/z:468[M-H]-;1H NMR(300MHz;CDCl3;TMS)δ:7.86(1H,d,J=15.6Hz),7.01(1H,s),6.25(1H,d,J=15.6Hz),4.10(2H,d,J=5.7Hz),3.89(3H,s),3.59(1H,m),3.42-2.93(4H,m),2.75(3H,s),2.54-0.85(26H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:167.5,146.8,144.8,142.1,132.1,126.1,123.1,116.5,106.1,64.5,57.6,55.9,48.0,47.5,45.8,42.6,38.8,37.8,37.5,36.6,30.5,28.6,26.9,26.4,23.9,22.9,22.5,22.0,13.9,11.7ppm.
实施例3:C环氢化青藤碱A环1位引入异噁唑啉杂环取代基的青藤碱衍生物15a-18a、15b-18b的合成
如图2所示:1)将反应物用混合溶剂DMF/Et3N(5∶1 v/v)配制成2mL、0.5M的反应液:1-碘代C环氢化青藤碱3(413mg,1mmol);Pd(OAc)2(11.2mg,0.05mmol);PPh3(26.2mg,0.1mmol);丙烯酸甲酯(1mmol)。将盛有反应液的注射器置于微量注射泵上,设置流速为8μL/min;石英毛细管微反应器1置于油浴中,油浴温度85℃。2)将不同取代基的肟分别配制成1mL、1M的DMF溶液,盛于注射器中;将N-氯代丁二酰亚胺配制成1mL、1M的DMF溶液,盛于注射器中;将盛有反应液的两支注射器置于双通道微量注射泵上,设置流速4μL/min,石英毛细管微反应器2置于空气中,室温。3)微反应器1的反应液与微反应器2的反应液通过一个T-型混合器,进入微反应器3中进行反应,石英毛细管微反应器3置于油浴中,油浴温度70℃。反应液流出时,用水立即淬灭。待反应完成后,旋掉溶剂和水,加入10mL乙酸乙酯,用饱和食盐水洗涤(3×5mL),无水硫酸钠干燥,浓缩,并用硅胶柱将异构体与杂质初步分离,展开剂为:二氯甲烷/甲醇,用核磁鉴定两种异构体的比例后,再用硅胶柱分离异构体,得到青藤碱衍生物15a-18a、15b-18b。
化合物15,产率:87%;异构体比例:a∶b=34∶66。
异构体15a:mp:158-160℃;ESI-MS m/z:491[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.75-7.72(2H,m),7.42-7.40(3H,m),6.80(1H,s),6.14(1H,d,J=5.4Hz),4.26(1H,d,J=5.4Hz),3.83(3H,s),3.78(3H,s),3.39(1H,m),2.94(1H,m),2.72(1H,d,J=18Hz),2.64-2.56(2H,m),2.45(3H,s),2.08(1H,m),1.85-1.11(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:170.0,153.3,145.0,144.4,130.4,128.8,128.3,127.1,127.0,126.8,126.5,105.2,84.5,61.9,57.8,56.1,53.2,47.9,45.6,42.4,37.8,37.5,36.7,26.9,26.4,22.9,21.6ppm
异构体15b:mp:157-159℃;ESI-MS m/z:491[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:ppm;7.73-7.70(2H,m),7.44-7.41(3H,m),6.88(1H,s),6.19(1H,d,J=5.4Hz),4.21(1H,d,J=5.4Hz),3.86(3H,s),3.79(3H,s),3.43(1H,m),2.96(1H,m),2.86(1H,d,J=18Hz),2.66-2.58(2H,m),2.47(3H,s),2.09(1H,m),1.83-1.16(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:170.0,153.2,145.0,144.4,130.5,128.8,128.3,127.1,127.0,126.7,126.5,105.3,84.1,61.9,57.8,56.1,53.2,47.9,45.3,42.2,30.0,37.6,36.5,26.9,26.4,22.9,21.5ppm
化合物16,产率:91%;异构体比例:a∶b=42∶58。
异构体16a:mp:155-157℃;ESI-MS m/z:505[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.59(1H,s),7.47(1H,d,J=7.2Hz),7.28(2H,m),6.80(1H,s),6.11(1H,d,J=5.7Hz),4.26(1H,d,J=5.7Hz),3.83(3H,s),3.78(3H,s),3.43-3.38(1H,m),3.02(1H,m),2.78(1H,d,J=18Hz),2.72-2.63(2H,m),2.51(3H,s),2.45(3H,s),2.22-2.13(1H,m),1.93-1.12(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:170.1,153.5,145.1,144.4,138.6,131.3,128.7,128.2,127.3,127.2,126.5,125.5,124.0,105.4,84.3,62.0,58.1,56.1,53.2,47.9,45.2,42.2,37.7,37.1,36.6,26.8,26.3,22.8,21.8,21.3ppm.
异构体16b:mp:159-161℃;ESI-MS m/z:505[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.58(1H,s),7.47(1H,d,J=7.4Hz),7.28(2H,m),6.85(1H,s),6.19(1H,d,J=6.0Hz),4.23(1H,d,J=6.0Hz),3.84(3H,s),3.78(3H,s),3.44(1H,m),3.18-3.15(1H,m),2.95(1H,d,J=18Hz),2.77-2.73(1H,m),2.67-2.57(1H,m),2.56(3H,s),2.38(3H,s),2.32-2.23(1H,m),2.05-1.15(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:169.9,153.7,145.1,144.6,138.5,131.3,128.6,128.2,127.4,126.9,126.8,125.8,124.0,105.5,84.1,61.2,58.0,56.0,53.2,47.6,44.9,42.3,37.7,37.0,36.4,26.9,26.3,22.8,21.5,21.3ppm
化合物17,产率:94%;异构体比例:a∶b=35∶65。
异构体17a:mp:149-151℃;ESI-MS m/z:521[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.67(2H,d,J=8.8Hz),6.91(2H,d,J=8.8Hz),6.81(1H,s),6.10(1H,d,J=5.6Hz),4.21(1H,d,J=5.6Hz),3.83(3H,s),3.82(3H,s),3.77(3H,s),3.39(1H,m),2.88(1H,m),2.67(1H,d,J=17.6Hz),2.58-2.50(2H,m),2.41(3H,s),2.02(1H,m),1.79-0.89(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:170.2,161.2,152.9,144.9,144.3,128.4,127.4,127.2,126.1,120.8,114.2,105.1,84.2,62.1,57.6,56.0,55.3,53.1,47.8,46.1,42.5,38.0,37.9,36.9,27.0,26.5,23.0,21.5ppm
异构体17b:mp:156-158℃;ESI-MS m/z:521[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.66(2H,d,J=8.8Hz),6.91(2H,d,J=8.8Hz),6.84(1H,s),6.20(1H,d,J=5.6Hz),4.17(1H,d,J=5.6Hz),3.87(3H,s),3.83(3H,s),3.77(3H,s),3.42(1H,m),2.95(1H,m),2.85(1H,d,J=17.6Hz),2.51-2.46(2H,m),2.40(3H,s),2.07(1H,m),1.80-1.11(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:170.0,161.2,153.0,144.9,144.4,128.5,127.7,127.0,126.3,120.8,114.3,105.3,84.0,61.5,57.6,56.1,55.3,53.1,47.5,45.8,42.6,37.9,37.7,36.8,27.2,26.5,23.0,21.3ppm
青藤碱衍生物18,产率:86%;异构体比例:a∶b=39∶61。
异构体18a:mp:153-155℃;ESI-MS m/z:570,572[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.63-7.53(4H,m),6.77(1H,s),6.15(1H,d,J=5.4Hz),4.26(1H,d,J=5.4Hz),3.83(3H,s),3.78(3H,s),3.39(1H,m),3.01(1H,m),2.77(1H,d,J=18.0Hz),2.69-2.62(2H,m),2.49(3H,s),2.16(1H,m),1.90-1.11(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:169.9,152.7,145.0,144.5,132.0,128.2,127.1,126.5,126.0,124.8,123.1,105.0,84.7,62.1,57.6,55.3,53.1,47.8,46.1,42.5,38.0,37.9,36.9,27.0,26.5,23.0,21.5ppm。
异构体18b:mp:144-146℃;ESI-MS m/z:570,572[M+H]+;1H NMR(300MHz;CDCl3;TMS)δ:7.61-7.51(4H,m),6.81(1H,s),6.1(1H,d,J=6.0Hz),4.22(1H,d,J=6.0Hz),3.83(3H,s),3.77(3H,s),3.42(1H,m),3.10(1H,m),2.99(1H,d,J=18.0Hz),2.75-2.67(2H,m),2.58(3H,s),2.21(1H,m),1.87-1.14(10H,m)ppm;13C NMR(75MHz;CDCl3;TMS)δ:170.0,152.6,144.9,144.5,132.1,128.3,127.2,126.6,126.0,124.8,123.1,105.0,84.3,62.2,57.6,55.3,53.1,47.6,46.0,42.7,38.1,37.8,36.9,27.1,26.5,23.1,21.6ppm.
实施例4:青藤碱衍生物抑制LPS诱导巨噬细胞产生NO活性的测定(10μM)
小鼠单核巨噬细胞RAW264.7用含5%FBS、100U/mL青霉素、100μg/mL链霉素的H-DMEM培养基,在含5%CO2的37℃培养箱中培养。实验时,设置LPS对照组、阴性对照组、阳性药对照组和测试药物组,将细胞计数调整至每毫升4×106个细胞,种于96孔板中,每孔100μL细胞悬液。37℃培养箱中培养2小时后,除开阴性对照组,其余分别加入含有刺激物的培养基100μL。用Griess试剂检测细胞上清中的NO含量实验,培养48小时。
细胞培养上清中的NO含量通过Griess法测定亚硝酸盐的量来间接测定。按照试剂盒说明书操作,具体步骤如下:
1)将冷藏保存的Sulfanilamide溶液和NED溶液恢复至室温;
2)每孔吸取待测细胞培养上清50μL至96孔板中,分别加入50μLSulfanilamide溶液,室温避光10分钟;
3)每孔分别加入50μL NED溶液,室温避光10分钟;
4)30分钟内,用酶标仪检测540nm处的吸光值OD540。
化合物对NO释放的抑制率计算公式为:
抑制率(%)=[LPS对照组(OD540)-测试药物组(OD540)]/[LPS对照组(OD540)-阴性对照组(OD540)]×100
所得化合物活性测试结果如下:大多数化合物表现了较好的抑制作用,具有潜在的用于关节炎,风湿性关节炎及其抗炎作用。
化合物 | 抑制率% | 化合物 | 抑制率 | 化合物 | 抑制率 |
L-NMMA | 40.3±1.3 | 6b | 40.4±1.3 | 11b | 100.0±0.9 |
青藤碱 | 16.3±4.3 | 6c | 99.2±0.8 | 12a | 100.0±0.9 |
1 | 2.5±3.2 | 6d | 99.6±0.3 | 12b | 90.6±0.4 |
2 | 0.0±5.6 | 6e | 81.6±8.7 | 13a | 100.0±0.4 |
3 | 6.5±2.2 | 6f | 34.2±1.1 | 13b | 100.0±1.0 |
4 | 79.3±2.0 | 6g | 100.0±1.0 | 14a | 100.0±0.9 |
5a | 0.0±0.3 | 6h | 100.0±0.5 | 14b | 100.0±0.5 |
5b | 0.0±3.1 | 6i | 100.0±0.7 | 15a | 100.0±0.6 |
5c | 83.3±0.7 | 7a | 0.0±5.3 | 15b | 97.9±0.4 |
5d | 0.0±4.9 | 7b | 0.0±13.8 | 16a | 100.0±0.4 |
5e | 34.5±8.8 | 8a | 65.5±0.8 | 16b | 41.8±0.7 |
5f | 0.0±7.9 | 8b | 0.0±4.1 | 17a | 94.1±4.4 |
5g | 100.0±0.6 | 9a | 47.8±2.7 | 17b | 100.0±0.4 |
5h | 0.0±4.2 | 9b | 0.0±5.1 | 18a | 26.6±2.5 |
5i | 67.0±10.7 | 10a | 0.0±0.7 | 18b | 17.4±4.0 |
5j | 0.0±0.9 | 10b | 0.0±9.0 | ||
6a | 39.9±3.1 | 11a | 0.0±5.4 |
表中数据为抑制率,表示为平均值±标准偏差。化合物浓度为10μM。
Claims (4)
2.一种制备权利要求1所述的C环氢化青藤碱衍生物的方法,其特征在于,包括:首先以青藤碱为母核,锌汞齐还原成C环氢化青藤碱,与N-碘代丁二酰亚胺反应,得到1位碘取代的C环氢化青藤碱;在醋酸钯催化下与丙烯酸酯进行Heck反应,生成1位碳碳双键取代的C环氢化青藤碱衍生物。
4.权利要求1所述的C环氢化青藤碱衍生物在用于制备治疗抗炎药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010268980A CN101973938B (zh) | 2010-09-01 | 2010-09-01 | C环氢化青藤碱衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010268980A CN101973938B (zh) | 2010-09-01 | 2010-09-01 | C环氢化青藤碱衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101973938A CN101973938A (zh) | 2011-02-16 |
CN101973938B true CN101973938B (zh) | 2012-10-03 |
Family
ID=43573856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010268980A Expired - Fee Related CN101973938B (zh) | 2010-09-01 | 2010-09-01 | C环氢化青藤碱衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101973938B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103387578A (zh) * | 2012-05-08 | 2013-11-13 | 长沙理工大学 | 4-对氟苄氧基-6-羟基吗啡喃烷的合成 |
CN104672142B (zh) * | 2015-02-13 | 2017-08-04 | 江苏大学 | 二元结构青藤碱衍生物的制备及医药用途 |
CN113861114B (zh) * | 2019-06-28 | 2023-06-09 | 沈阳药科大学 | 吗啡烷类和双苄基异喹啉类生物碱化合物及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101092397A (zh) * | 2006-06-19 | 2007-12-26 | 湖南正清制药集团股份有限公司 | 一种青藤碱结构改造化合物及其制备方法 |
CN101798285A (zh) * | 2010-02-10 | 2010-08-11 | 中国科学院上海有机化学研究所 | 一种青藤碱衍生物、合成方法及其用途 |
-
2010
- 2010-09-01 CN CN201010268980A patent/CN101973938B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101092397A (zh) * | 2006-06-19 | 2007-12-26 | 湖南正清制药集团股份有限公司 | 一种青藤碱结构改造化合物及其制备方法 |
CN101798285A (zh) * | 2010-02-10 | 2010-08-11 | 中国科学院上海有机化学研究所 | 一种青藤碱衍生物、合成方法及其用途 |
Non-Patent Citations (1)
Title |
---|
李玉峰等.从青藤碱制备具有(+)-C-Normorphinan 骨架的化合物.《有机化学》.2009,第29卷(第2期),259-264. * |
Also Published As
Publication number | Publication date |
---|---|
CN101973938A (zh) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101948430A (zh) | 青藤碱衍生物及其制备方法和应用 | |
Rali et al. | Semisynthesis of derivatives of oleanolic acid from Syzygium aromaticum and their antinociceptive and anti-inflammatory properties | |
CN102675389B (zh) | 5-碘-4-硫-2’-脱氧尿苷及衍生物及其合成方法 | |
CN101973938B (zh) | C环氢化青藤碱衍生物及其制备方法和应用 | |
Yang et al. | Semisynthesis and biological evaluation of some novel Mannich base derivatives derived from a natural lignan obovatol as potential antifungal agents | |
CN108026046A (zh) | 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途 | |
CN109422744A (zh) | 苦参碱衍生物及其合成和在防治植物病虫害方面的应用 | |
CN103864642B (zh) | 大黄酸衍生物及其合成方法和用途 | |
CN110330498A (zh) | 一种螺(3,3’-苯基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 | |
CN109776528A (zh) | 一种2-(吲哚-3-基)-吡啶并咪唑及其应用 | |
CN100415745C (zh) | 作为可诱导的no合成酶抑制剂的咪唑并吡啶衍生物 | |
CN102887869B (zh) | 3‑酰胺基‑1,2,4‑苯并三嗪类在制备肿瘤增敏剂中的用途 | |
CN109232703A (zh) | 含16-(1′-芳香基-1′,2′,3′-三氮唑)亚甲基-雄甾-17-酮衍生物 | |
CN107698648A (zh) | 含胆甾醇的萘酰亚胺类衍生物及其合成和应用 | |
CN107011312A (zh) | 片叶苔素d含氮衍生物及其制备方法和在治疗肿瘤疾病中的用途 | |
CN112194697B (zh) | 一种新型三萜类化合物及其制备治疗心血管疾病药物的用途 | |
CN102702297B (zh) | 胆酸-萘酰亚胺类化合物的制备方法 | |
CN101407515A (zh) | 用作cdk抑制剂的喹啉类多环化合物 | |
CN101851271A (zh) | 蓝萼丁素衍生物、制备方法及其用途 | |
CN107304214B (zh) | 水溶性银杏内酯b氨基甲酸酯衍生物及其制备方法和用途 | |
CN101434579A (zh) | 附子灵酯化衍生物与合成方法及应用 | |
CN115785189B (zh) | 一种5α,8α-过氧化甾醇-17-苯基噻唑衍生物及其合成方法和应用 | |
CN103360327B (zh) | 一种苯并吩嗪衍生物及其制备方法和应用 | |
CN102690313B (zh) | 胆酸-萘酰亚胺类化合物及其应用 | |
RU2534987C1 (ru) | Амиды ламбертиановой кислоты, обладающие анальгетической активностью и стимулирующим действием |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121003 Termination date: 20150901 |
|
EXPY | Termination of patent right or utility model |